• Pfizer Inc., of New York, said the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for Xeljanz (tofacitnib citrate) for the treatment of adults with moderate to severe active rheumatoid arthritis. The CHMP said it is of the opinion that the drug does not demonstrate a favorable risk-benefit profile and recommended against marketing authorization. Pfizer intends to appeal the opinion and seek a re-examination by CHMP. Xeljanz, a JAK inhibitor, gained approval in the U.S. last year. (See BioWorld Today, Nov. 8, 2012.)